BioProcess International’s Post

What is top of mind across cell therapy?... While ISCT, International Society for Cell & Gene Therapy annual meeting is in the rearview, the highlights, key trends, and hurdles remain! We asked stakeholders from companies like Ori Biotech, xcellbio, and uBriGene Biosciences Inc., and investors from AVANT BIO what their key takeaways are. Check it out here: 👉 https://lnkd.in/dEUWbKAi The long and short, you ask? 1️⃣ Manufacturing Innovations and Challenges: The field is rapidly advancing with new automated platforms to address current suboptimal workflows. 2️⃣ Technological Advancements and Excitement: The conference saw multiple launches of new systems, like Ori's IRO®, Cytiva's enhanced Sefia system, and Xcellbio's AVATAR. 3️⃣ Focus on Potency and Data-Driven Processes: There was a strong emphasis on developing better potency assessments and leveraging data-driven processes. Did you attend the conference? What was your key takeaway? Let me know! #celltherapy #pharma #healthcare

👀 TLDR Biotech's daily newsletter has hit 1000+ subs - and it's only the beginning! A big thank you to everyone that's subscribed so far and helped spread the word. Extra special thanks to our premium subscribers, sponsors, and to everyone that's taken time to provide feedback on the newsletter though written or virtual interviews. Another exciting milestone: next week I'll be attending my first conference as TLDR Biotech, covering all things cell & gene therapy at Meeting on the Mesa in Phoenix, Arizona! My calendar is nearly chock-a-block, but if you're open to giving your 2 cents on the CGT industry, hmu through the partnering app or here on LinkedIn. (And if you want the top biotech and pharma stories straight to your inbox, organized into only one daily email, sign-up to TLDR Biotech here: https://tldrbio.tech/)

To discuss how to de-risk your viral vector prior to clinical trials, please reach out to our team at #ISCT2024 in Vancouver. Farzin Farzaneh, PhD Traci Kyes Makis Sigalas

How can we address the hurdles limiting scalable viral vector manufacturing for cell and gene therapy? A new international consortium has £1.1M funding for a fresh approach. Abselion is delighted to be joining VVector Bio, the National Research Council Canada / Conseil national de recherches Canada, and Revvity to apply a multifaceted strategy to unlock viral vector production capabilities. Jointly funded by Innovate UK and the NRC, as part of the Biomanufacturing of Biologics and Advanced Therapies programme, the project will combine detailed multi-omics analysis of the HEK-293 cell line with a new approach to manufacturing and process monitoring empowered by at-line and on-line process analytics.   The project seeks to develop the next-generation cell platform for viral vector production, improving yields, quality, scalability and lowering costs, to ultimately help to accelerate the creation of therapies for patients. Learn more: https://lnkd.in/eY6CrTej #genetherapy, #celltherapy, #bioprocessing, #drugdevelopment #genomics

🔔  Circular RNA news ! ⭕ Orna Therapeutics revealed the acquisition of ReNAgade Therapeutics ! ORNA is a main player in the field of circular RNA, developing circular RNA (oRNA®) therapeutics and ReNAgade unveiled new LNPs for delivering mRNA to extra-hepatic tissues. According to ORNA’s press release, this strategic move « unifies two industry-leading circles with the knowhow to significantly expand circular RNA engineering and delivery technologies and advance in vivo CAR and gene editing approaches for a range of diseases ».   💡 Get more information on ReNAgade Therapeutics ionizable lipids with KnowMade’s Insight https://lnkd.in/eGvc_-R5   💡  Get more information on circular RNA with KnowMade’s Insight https://lnkd.in/gns4SXhP 🔹 For an overview of KnowMade’s activities dedicated to mRNA therapeutics see the dedicated webpage 👇 https://lnkd.in/gney6ZhX   #mrna #circular #LNP

The biotech industry is evolving at rapid speed, and staying ahead demands a proactive approach. In this on-demand webinar, our CTO, Hanna P. Lesch, along with industry experts share their practical insights to help you navigate the challenges and seize opportunities in cell and gene therapy. By watching, you'll learn: 🔍 Key strategies to secure vital funding in a competitive market 🏆 How to refine your operations while maintaining top-notch quality and regulatory compliance 🌐 How to overcome hurdles to get your therapies approved and into the market 💰 Tips for mastering the complexities of pricing to ensure your therapies reach patients and remain profitable Watch on-demand below. https://lnkd.in/e7a-zrZx #GeneTherapy #CGT

🚨Just two days away... Have you factored in mitigating innate antiviral defenses into your scale-up model? Deciding whether to scale up or out your cell therapy process? Our experts Andrea Vervoort, Jondavid de Jong, & Jean-Simon Diallo will cover all you need to know about antiviral defenses and present how Virica uses bioprocess modeling to evaluate the benefits of enhancing technologies such as our Viral Sensitizer (VSE) platform by observing key cost drivers and identifying how they are influenced by even modest improvements in yield. Expect to learn: -The impact of innate antiviral defenses on viral vector yield and quality -An overview of the mode of action and benefits of VSEs -A case study demonstrating how VSEs can enhance AAV yield and scale-up efficiency. -Employing bioprocess modeling to determine long-term cost benefits of VSE-mediated enhancement of AAV in HEK293 cells. The webinar will be hosted with our partner BioInsights (Cell and Gene Insights) on Jan 25, 2024; 11:00 EST, 8:00 PST, 16:00GMT, 17:00 CET. Register: https://lnkd.in/ez5Euymk

Big Pharma spending continues post #jpm2024 with AstraZeneca acquiring Gracell Biotechnologies for $1.2B in a cash deal. For those unfamiliar, Gracell they are a Biotech founded in 2017 and HQ'd out of China. They have been making great progress with developing Car-T based therapeutics. Particularly their approach looks to disrupt the conventional approaches to both autologous and allogeneic CAR-T cell therapies. The deal marks yet another move by AZ to build a footprint in the Cell & Gene Therapy space where they have been playing catch up with multiple deals over recent months. #biotechnology #lifesciences #aquisitions

Got to make your current trials and tribulations a priority to learn from and meet with those offering possible solutions. Unless you have the luxury of just cruising the meet following your personal interests :-)

💫 What a busy start today in London! 🇬🇧 There's still time to meet this afternoon, and if you don't catch us today, there's also an opportunity tomorrow. 👉🏼 We're ready for another productive day at booth #111! 💡 Discuss together how ReiThera’s capabilities can advance your gene therapy program or viral vaccine from preclinical to clinical and commercial production. #gmp #biotech #biotechnology #genetherapy #cellandgenetherapy #advancedtherapies #adtherapies24